A website specializing in Lifestyle Modification of Chronic Non-Cancer Pain

Of all Europeans who say they suffer from CNCP, 21% have had their chronic pain for more than 20 years. Chronic musculoskeletal pain is the most frequent type of pain suffered, followed by arthritis pain.  Vioxx is a “Cox2 inhibitor” prescribed for musculoskeletal and arthritis pain below 5, on a scale from 1 to 10, where 10 is “the worst pain imaginable.” While Cox2’s reduce GI risk, Vioxx had to be voluntarily withdrawn from the market when a higher-than-usual cardiovascular risk and number of “adverse events” was discovered. However, 2 other Cox2’s – Bextra and Celebrex – remain on the market. Yet, no pain drug has the long-term studies that will support their use without adverse events for the average 7 years that most CNCP patients have had their pain. Going back to using NSAIDs (the “non-steroidal anti-inflammatories”) chronically creates the same GI risk, tinnitus and the need for discontinuing the drug, so going back to less-strong medications is not a good long-term option. The issue now is, Will the demise of the Cox2’s lead to increased use of opioids, with the long-overdue deregulation for legitimate CNCP patients?